“…Chemically engineering nanomaterials to exert potent anticancer activity, such as radiosensitizing cancer cells, − exhausting energy metabolism, − and generating reactive oxygen species (ROS), − has the promising potential to achieve satisfactory therapeutic outcomes. More recently, inspired by natural metalloenzymes, − fine-defined single-atom nanozymes (SAzymes), in which metal atoms as active sites are monodispersed on supports, have drawn significant attention for their ability to trigger abnormally low or high levels of intracellular biomarkers through catalysis to induce cancer-specific cytotoxicity, thereby rapidly emerging as a competitive alternative for therapeutic use in oncology. − For instance, oxidoreductase-like SAzymes that respond to the tumor microenvironment enable the conversion of less reactive H 2 O 2 into highly cytotoxic hydroxyl radicals ( • OH) for chemodynamic therapy or into O 2 for overcoming tumor hypoxia toward the following treatments. − However, the catalytic active sites of most SAzymes are identified predominantly as their superficial atoms rather than their inner moieties, which severely limits therapeutic efficacy as the result of this deficient catalytic activity. − Moreover, intratumoral H 2 O 2 , although it is higher compared to normal cells, remains largely insufficient, thus presenting another challenge to enzymatic therapy owing to H 2 O 2 -dependent • OH generation. − In addition, overexpressed glutathione (GSH) can quickly consume • OH produced by SAzymes at the tumor sites, further blunting its anticancer efficacy. − …”